Spiolto Respimat Innöndunarlausn 2,5/2,5 míkróg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

spiolto respimat innöndunarlausn 2,5/2,5 míkróg

boehringer ingelheim international gmbh* - tiotropii bromidum inn; olodaterolum hýdróklóríð - innöndunarlausn - 2,5/2,5 míkróg

Aflunov Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

aflunov

seqirus s.r.l.  - yfirborðs mótefnavakar gegn inflúensuveiru (haemagglutinin og neuraminidasa) álag: a / tyrkland / tyrkland / 1/05 (h5n1) -likk álag (nibrg-23) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirflokk inflúensu-a vírus. Þetta merki er byggt á immunogenicity gögn úr heilbrigðum einstaklingar frá 18 ára aldri og áfram eftir gjöf tvo skammta af bóluefni sem inniheldur/duck/1/05 (h5n1)-eins og álag. Ára ætti að vera notuð í samræmi við opinbera tillögur.

Focetria Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - bólusetningar gegn inflúensu - fyrirbyggjandi meðferð inflúensu af völdum a (h1n1v) 2009 veirunnar. benda ætti að vera notuð í samræmi við opinbera leiðsögn.

Foclivia Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

foclivia

seqirus s.r.l.  - inflúensuveiru yfirborðs mótefnavaka, óvirkt: a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bólusetningar gegn inflúensu - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið. bólusetning gegn heimsfaraldri inflúensu ætti að nota í samræmi við opinbera leiðbeiningar.

Carbocain Stungulyf, lausn 10 mg/ml Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

carbocain stungulyf, lausn 10 mg/ml

aspen pharma trading limited - mepivacainum hýdróklóríð - stungulyf, lausn - 10 mg/ml

Carbocain Stungulyf, lausn 20 mg/ml Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

carbocain stungulyf, lausn 20 mg/ml

aspen pharma trading limited - mepivacainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Carbocain adrenalin Stungulyf, lausn 10 mg + 5 µg/ml Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

carbocain adrenalin stungulyf, lausn 10 mg + 5 µg/ml

aspen pharma trading limited - mepivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg + 5 µg/ml

Zoonotic Influenza Vaccine Seqirus Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - bóluefni - active immunisation against h5 subtype of influenza a virus.

Macugen Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

macugen

pharmaswiss ceska republika s.r.o - pegaptanib - wet macular degeneration - augnlækningar - macugen er ætlað fyrir meðferð neovascular (blautur) aldri-tengjast ský á auga (rÍsa).

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - yfirborðs mótefna gegn inflúensuveiru (haemagglutinin og neuraminidasa) á stofn a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirgerð inflúensu a veiru. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.